269 related articles for article (PubMed ID: 27836437)
1. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.
Haber P; Arana J; Pilishvili T; Lewis P; Moro PL; Cano M
Vaccine; 2016 Dec; 34(50):6330-6334. PubMed ID: 27836437
[TBL] [Abstract][Full Text] [Related]
2. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
Miller ER; Moro PL; Cano M; Lewis P; Bryant-Genevier M; Shimabukuro TT
Vaccine; 2016 May; 34(25):2841-6. PubMed ID: 27087150
[TBL] [Abstract][Full Text] [Related]
3. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
[TBL] [Abstract][Full Text] [Related]
5. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
6. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
[TBL] [Abstract][Full Text] [Related]
7. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
Haber P; Moro PL; Ng C; Lewis PW; Hibbs B; Schillie SF; Nelson NP; Li R; Stewart B; Cano MV
Vaccine; 2018 Jan; 36(4):559-564. PubMed ID: 29241647
[TBL] [Abstract][Full Text] [Related]
8. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
[TBL] [Abstract][Full Text] [Related]
9. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
11. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
[TBL] [Abstract][Full Text] [Related]
12. Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018.
Haber P; Moro PL; Ng C; Dores GM; Perez-Vilar S; Marquez PL; Cano M
Vaccine; 2020 Feb; 38(6):1476-1480. PubMed ID: 31883809
[TBL] [Abstract][Full Text] [Related]
13. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
14. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
Sukumaran L; McNeil MM; Moro PL; Lewis PW; Winiecki SK; Shimabukuro TT
Clin Infect Dis; 2015 May; 60(10):e58-65. PubMed ID: 25637587
[TBL] [Abstract][Full Text] [Related]
15. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
Moro PL; Woo EJ; Marquez P; Cano M
Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434
[TBL] [Abstract][Full Text] [Related]
16. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.
Haber P; Moro PL; Cano M; Lewis P; Stewart B; Shimabukuro TT
Vaccine; 2015 Apr; 33(16):1987-92. PubMed ID: 25678241
[TBL] [Abstract][Full Text] [Related]
17. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
[TBL] [Abstract][Full Text] [Related]
18. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries.
Thompson A; Gurtman A; Patterson S; Juergens C; Laudat F; Emini EA; Gruber WC; Scott DA
Vaccine; 2013 Oct; 31(45):5289-95. PubMed ID: 23973321
[TBL] [Abstract][Full Text] [Related]
19. Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.
Moro PL; Woo EJ; Paul W; Lewis P; Petersen BW; Cano M
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004846. PubMed ID: 27410239
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
